Breast cancer, Secondary cancers
Results
Phase 3
This trial was for people with breast cancer that:
could not be removed with surgery or had spread to another part of the body
had a large number of hormone receptors ( or HR positive cancer)
had a small number of receptors for the protein HER2 ()
The trial compared standard chemotherapy with a called datopotamab deruxtecan.
The results showed that datopotamab deruxtecan can help stop breast cancer growing more than standard chemotherapy. This is for people whose cancer has spread or can't be removed with surgery.
Recruitment start: 18 October 2021
Recruitment end: 22 December 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
AstraZeneca
Last reviewed: 24 Sept 2026
CRUK internal database number: 17902